Polypharmacy, drug-drug interactions, anticholinergic burden and cognitive outcomes: a snapshot from a community-dwelling sample of older men and women in northern Italy
Polypharmazie, Arzneimittel-Interaktionen, anticholinerge Last und kognitive Ergebnisse: Momentaufnahme aus einer in der Gemeinde lebenden Stichprobe älterer Männer und Frauen in Norditalien
European Journal of Ageing · 2024-12 · 21 (1)
DOI: 10.1007/s10433-024-00806-0 ↗Auf einen Blick
In einer Querschnittsstudie bei älteren Erwachsenen waren Polypharmazie, potenzielle Arzneimittel-Interaktionen und anticholinerge Last häufig. Eine hohe anticholinerge Last war mit MCI und schlechter Exekutivfunktion verbunden.
Fragestellung
Wie häufig sind Polypharmazie, potenzielle Arzneimittel-Interaktionen und anticholinerge Last bei älteren Menschen, und wie sind sie mit kognitiven Ergebnissen verbunden?
Methode
Querschnittsdaten von 636 in der Gemeinde lebenden Erwachsenen aus der NutBrain-Studie (2019–2023). Analyse von Polypharmazie (≥ 5 Medikamente/Tag), potenziellen DDIs und ACB mittels logistischer Regression, adjustiert für Störfaktoren; geschlechtsspezifische Analyse.
Ergebnisse
27,2 % waren Polypharmazie ausgesetzt, 42,3 % potenziellen DDIs und 19 % kumulativer ACB. Bei schwerer ACB (≥ 3) waren die Chancen für MCI erhöht (OR 3,34; 95 %-KI 1,35–8,25) und für schlechte Exekutivfunktion (OR 4,45; 95 %-KI 1,72–11,49).
Schlussfolgerung der Autor:innen
Polypharmazie, potenzielle DDIs und anticholinerge Arzneimittel waren bei in der Gemeinde lebenden älteren Menschen sehr häufig. Die ACB-Exposition war mit MCI verbunden, besonders mit schlechter Exekutivfunktion.
Kernaussagen
- Polypharmazie: 27,2 %; potenzielle DDIs: 42,3 %; ACB: 19 %
- Schwere ACB war mit MCI assoziiert: OR 3,34 (95 %-KI 1,35–8,25)
- ACB war mit schlechter Exekutivfunktion assoziiert: OR 4,45 (95 %-KI 1,72–11,49)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Ageing, online erschienen am 29.03.2024. Verfasst von Elena Perdixi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, IRCCS Humanitas Clinical and Research Center, Via Alessandro Manzoni, 56, 20089, Rozzano, MI, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Consiglio Nazionale Delle Ricerche.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Polypharmacy (PP) use is very common in older people and may lead to drug-drug interactions (DDIs) and anticholinergic burden (ACB) that may affect cognitive function. We aimed to determine the occurrence of PP, potential DDIs and ACB and their role in cognitive outcomes in an older population. Cross-sectional data from 636 community-dwelling adults (73.2 ± 6.0 SD, 58.6% women) participating in the NutBrain study (2019–2023) were analyzed. Participants were asked about their medication use, and data on potential DDIs and ACB were extracted. The associations of PP (≥ 5 drugs/day), potential DDIs, and ACB with mild cognitive impairment (MCI) and specific cognitive domains were assessed using logistic regression adjusted for confounders. Sex-stratified analysis was performed. Overall, 27.2% of the participants were exposed to PP, 42.3% to potential DDIs and 19% to cumulative ACB. Women were less exposed to PP and more exposed to ACB than men. In multivariate analysis, the odds of having MCI (24%) were three times higher in those with severe ACB (≥ 3) (OR 3.34, 95%CI 1.35–8.25). ACB was positively associated with poor executive function (OR 4.45, 95%CI 1.72–11.49) and specifically with the Frontal Assessment Battery and neuropsychological tests of phonological and semantic fluency. In sex-stratified analysis, ACB was statistically significantly associated with MCI and executive function in women and with memory in men. PP, potential DDIs and anticholinergics use are very common in community-dwelling older people. ACB exposure is associated with MCI, particularly with poor executive function. Clinicians are encouraged to be vigilant when prescribing anticholinergics. Trial registration : Trial registration number NCT04461951, date of registration July 7, 2020 (retrospectively registered, ClinicalTrials.gov).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, IRCCS Humanitas Clinical and Research Center, Via Alessandro Manzoni, 56, 20089, Rozzano, MI, Italy.
- Neuropsychology Lab/Center for Cognitive Disorders and Dementia IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.
- Clinical Neuroscience Unit of Dementia, Dementia Research Center, IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.
- Unit of Behavioral Neurology, IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy.
- Institute of Biomedical Technologies - National Research Council, Via Fratelli Cervi 93, 20054, Segrate, MI, Italy.
- Neuropsychology Lab/Center for Cognitive Disorders and Dementia IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia, Italy. federica.prinelli@itb.cnr.it.
Förderung
- Ministero della Salute
- Consiglio Nazionale Delle Ricerche
Zitieren
APA
Perdixi, E., Cotta Ramusino, M., Costa, A., Bernini, S., Conti, S., Jesuthasan, N., Severgnini, M., Prinelli, F., & NutBrain Study Group (2024). Polypharmacy, drug-drug interactions, anticholinergic burden and cognitive outcomes: a snapshot from a community-dwelling sample of older men and women in northern Italy. European Journal of Ageing, 21(1). https://doi.org/10.1007/s10433-024-00806-0
Vancouver
Perdixi E, Cotta Ramusino M, Costa A, Bernini S, Conti S, Jesuthasan N, et al. Polypharmacy, drug-drug interactions, anticholinergic burden and cognitive outcomes: a snapshot from a community-dwelling sample of older men and women in northern Italy. European Journal of Ageing. 2024;21(1). doi:10.1007/s10433-024-00806-0
BibTeX
@article{Perdixi2024,
author = {Perdixi, Elena and Cotta Ramusino, Matteo and Costa, Alfredo and Bernini, Sara and Conti, Silvia and Jesuthasan, Nithiya and Severgnini, Marco and Prinelli, Federica and NutBrain Study Group, NutBrain Study Group},
title = {Polypharmacy, drug-drug interactions, anticholinergic burden and cognitive outcomes: a snapshot from a community-dwelling sample of older men and women in northern Italy},
journal = {European Journal of Ageing},
year = {2024},
volume = {21},
number = {1},
doi = {10.1007/s10433-024-00806-0}
}
EUVIMED